Literature DB >> 30277521

New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer.

Aritoshi Hattori1, Kazuya Takamochi1, Shiaki Oh1, Kenji Suzuki1.   

Abstract

In the eighth edition of the TNM classification of lung cancer, the prognostic impact of tumor size is emphasized as a descriptor of all T categories. Especially in lung cancer where tumor size is 5 cm or less, the 1-cm cutoff point significantly differentiated the survival outcome. In addition, the new staging categories were assigned, namely, Tis (adenocarcinoma in situ) and T1mi (minimally invasive adenocarcinoma). Furthermore, the measurement of a radiological solid component size excluding the ground glass opacity component or pathological invasive size without a lepidic component was proposed for deciding the cT/pT categories for lung adenocarcinoma. The N descriptors were kept the same as in the eventh edition on the whole, however, quantification of nodal disease had a prognostic impact based on the number of nodal stations involved in the eighth edition, i.e. N1a as a single N1 station, N1b as a multiple N1 station, N2a1 as a single N2 station without N1 (skip metastasis), N2a2 as a single N2 station with N1 disease, and N2b as a multiple N2 station. In the M descriptors, subclassification was performed based on the location or numbers of distantly metastatic lesions, i.e. M1a as any intrathoracic metastases, M1b as a single distant metastatic lesion in one organ, and M1c as multiple distant metastases in either a single organ or multiple organs. Survival analysis of the eighth edition of the TNM classification clearly separated the distinct groups, however, unsolved issues still remain that should be discussed and further revised for the forthcoming TNM staging system.

Entities:  

Mesh:

Year:  2019        PMID: 30277521     DOI: 10.1093/jjco/hyy142

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  14 in total

1.  Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.

Authors:  J Jin; Y Xu; X Hu; M Chen; M Fang; Q Hang; M Chen
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

2.  Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma.

Authors:  Yasemin Saygideger; Alper Avci; Emine Bagir; Burcu Saygıdeğer Demir; Aycan Sezan; Mucahit Ekici; Oya Baydar; Özgür Cem Erkin
Journal:  Discov Oncol       Date:  2022-01-22

Review 3.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

4.  Correlation between Skip N2 Metastases and SUVmax, Long Diameter of Tumor, and Ki67 Expression in Patients with Non-Small-Cell Lung Cancer.

Authors:  Wang Jian; Peng Ming-Ya; Xu Long-Bao; Zhao Jun; Shao Guo-Qiang
Journal:  Biomed Res Int       Date:  2020-04-25       Impact factor: 3.411

5.  MicroRNAs in sputum specimen as noninvasive biomarkers for the diagnosis of nonsmall cell lung cancer: An updated meta-analysis.

Authors:  Xiaoyun Zhang; Qian Wang; Shijie Zhang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

6.  A highly expressed mRNA signature for predicting survival in patients with stage I/II non-small-cell lung cancer after operation.

Authors:  Meihua Li; Zhiyi He; Nan Ma; Lu Si; Meiling Yang
Journal:  Sci Rep       Date:  2021-03-12       Impact factor: 4.379

7.  Chaperone-Mediated Autophagy Markers LAMP2A and HSPA8 in Advanced Non-Small Cell Lung Cancer after Neoadjuvant Therapy.

Authors:  Tereza Losmanova; Philipp Zens; Amina Scherz; Ralph A Schmid; Mario P Tschan; Sabina Berezowska
Journal:  Cells       Date:  2021-10-13       Impact factor: 6.600

8.  Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma.

Authors:  Masayuki Nakao; Katsunori Oikado; Yoshinao Sato; Kohei Hashimoto; Junji Ichinose; Yosuke Matsuura; Sakae Okumura; Hironori Ninomiya; Mingyon Mun
Journal:  JTO Clin Res Rep       Date:  2022-01-21

9.  Pretreatment plasma d-dimer levels as an independent prognostic factor for overall survival among patients with advanced non-small-cell lung cancer.

Authors:  Qianfei Liu; Jianbo He; Ruiling Ning; Liping Tan; Aiping Zeng; Shaozhang Zhou
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

10.  Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy.

Authors:  Meifang Liu; Jie Yang; Lagen Wan; Rui Zhao
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.